Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development expense	$ 21,697	$ 16,923
General and administrative expense	7,233	7,423
Total operating expenses	28,930	24,346
Loss from operations	(28,930)	(24,346)
Other income (expense):
Interest income	1,480	85
Other income (expense)	(10)	7
Total other income (expense)	1,470	92
Consolidated net loss and comprehensive loss	$ (27,460)	$ (24,254)
Net loss per common share, basic	$ (0.58)	$ (0.65)
Net loss per common share, diluted	$ (0.58)	$ (0.65)
Weighted-average shares of common stock outstanding, basic	47,578,418	37,322,360
Weighted-average shares of common stock outstanding, diluted	47,578,418	37,322,360